Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma

about

Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma

Item

http://www.wikidata.org/entity/Q58571031

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Late toxicity in long-term sur ...... r newly diagnosed glioblastoma

@en

Late toxicity in long-term sur ...... r newly diagnosed glioblastoma

@nl

type

Item

label

Late toxicity in long-term sur ...... r newly diagnosed glioblastoma

@en

Late toxicity in long-term sur ...... r newly diagnosed glioblastoma

@nl

prefLabel

Late toxicity in long-term sur ...... r newly diagnosed glioblastoma

@en

Late toxicity in long-term sur ...... r newly diagnosed glioblastoma

@nl

P1476

Late toxicity in long-term sur ...... r newly diagnosed glioblastoma

@en

P2093

Andra V Krauze

http://www.w3.org/2001/XMLSchema#string

Diane J Holdford

http://www.w3.org/2001/XMLSchema#string

Joanna Shih

http://www.w3.org/2001/XMLSchema#string

Kevin Camphausen

http://www.w3.org/2001/XMLSchema#string

Lindsay Rowe

http://www.w3.org/2001/XMLSchema#string

Megan Mackey

http://www.w3.org/2001/XMLSchema#string

Michal G Chang

http://www.w3.org/2001/XMLSchema#string

Philip J Tofilon

http://www.w3.org/2001/XMLSchema#string

Theresa Cooley

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

A randomized trial of bevacizumab for newly diagnosed glioblastoma

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.

RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma

Molecular targets for tumor radiosensitization.

P304

246-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NOP/NPY009

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30402263

http://www.w3.org/2001/XMLSchema#string

P932

6213944

http://www.w3.org/2001/XMLSchema#string